Abstract
Little is known about the effect of ketamine, which has a rapid and robust effect on depressive symptoms and suicidal ideation, on cognition in adolescents. Researchers in China conducted a randomized controlled trial on 51 participants 13–18 years old with major depression disorder (MDD) and suicidal ideation. The participants received esketamine or midazolam in three intravenous infusions. Processing speed, working memory, verbal learning, and visual learning were assessed at days 0, 6, and 12. The researchers found that cognition was not harmed by the esketamine, and in fact esketamine improved processing speed. [Lan, X., Wang, C., Zhang, F., et al. (2023, Sep 14). Short‐term cognitive effects of repeated‐dose esketamine in adolescents with major depressive disorder and suicidal ideation: A randomized controlled trial. Child Adolesc Psychiatry Ment Health, 17(1), 108. http://doi.org/10.1186/s13034‐023‐00647‐2.]
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: The Brown University Child & Adolescent Psychopharmacology Update
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
